AGIO
Price
$36.38
Change
-$0.68 (-1.83%)
Updated
Aug 8, 04:21 PM (EDT)
Capitalization
2.19B
83 days until earnings call
IDYA
Price
$22.92
Change
+$0.51 (+2.28%)
Updated
Aug 8, 04:39 PM (EDT)
Capitalization
1.96B
95 days until earnings call
Interact to see
Advertisement

AGIO vs IDYA

Header iconAGIO vs IDYA Comparison
Open Charts AGIO vs IDYABanner chart's image
Agios Pharmaceuticals
Price$36.38
Change-$0.68 (-1.83%)
Volume$600
Capitalization2.19B
IDEAYA Biosciences
Price$22.92
Change+$0.51 (+2.28%)
Volume$400
Capitalization1.96B
AGIO vs IDYA Comparison Chart in %
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. IDYA commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Hold and IDYA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (AGIO: $37.07 vs. IDYA: $22.41)
Brand notoriety: AGIO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 66% vs. IDYA: 63%
Market capitalization -- AGIO: $2.19B vs. IDYA: $1.96B
AGIO [@Biotechnology] is valued at $2.19B. IDYA’s [@Biotechnology] market capitalization is $1.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • AGIO’s TA Score: 4 bullish, 5 bearish.
  • IDYA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AGIO is a better buy in the short-term than IDYA.

Price Growth

AGIO (@Biotechnology) experienced а -0.40% price change this week, while IDYA (@Biotechnology) price change was -7.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.21%. For the same industry, the average monthly price growth was +6.59%, and the average quarterly price growth was +12.79%.

Reported Earning Dates

AGIO is expected to report earnings on Oct 30, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+0.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($2.19B) has a higher market cap than IDYA($1.96B). AGIO YTD gains are higher at: 12.812 vs. IDYA (-12.802). IDYA has higher annual earnings (EBITDA): -356.46M vs. AGIO (-456.28M). AGIO has more cash in the bank: 939M vs. IDYA (693M). IDYA has less debt than AGIO: IDYA (26M) vs AGIO (48.8M). AGIO has higher revenues than IDYA: AGIO (40.9M) vs IDYA (7M).
AGIOIDYAAGIO / IDYA
Capitalization2.19B1.96B112%
EBITDA-456.28M-356.46M128%
Gain YTD12.812-12.802-100%
P/E Ratio3.34N/A-
Revenue40.9M7M584%
Total Cash939M693M135%
Total Debt48.8M26M188%
FUNDAMENTALS RATINGS
AGIO vs IDYA: Fundamental Ratings
AGIO
IDYA
OUTLOOK RATING
1..100
7671
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
10078
SMR RATING
1..100
1696
PRICE GROWTH RATING
1..100
4548
P/E GROWTH RATING
1..100
72100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (42) in the Biotechnology industry is in the same range as IDYA (62) in the null industry. This means that AGIO’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (78) in the null industry is in the same range as AGIO (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for IDYA (96) in the null industry. This means that AGIO’s stock grew significantly faster than IDYA’s over the last 12 months.

AGIO's Price Growth Rating (45) in the Biotechnology industry is in the same range as IDYA (48) in the null industry. This means that AGIO’s stock grew similarly to IDYA’s over the last 12 months.

AGIO's P/E Growth Rating (72) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that AGIO’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOIDYA
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 16 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
75%
Bearish Trend 2 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VFSNX261.25N/A
N/A
Vanguard FTSE All-Wld ex-US SmCp Idx Ins
CHCGX57.43N/A
N/A
Chesapeake Growth
CFVLX33.30N/A
N/A
Commerce Value
FLUIX28.43N/A
N/A
Fidelity Advisor Stk Selec Lg Cp Val I
DDVCX14.05-0.02
-0.14%
Macquarie Value C

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with LGND. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then LGND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
-1.72%
LGND - AGIO
52%
Loosely correlated
+3.19%
ZYME - AGIO
48%
Loosely correlated
-3.03%
CRNX - AGIO
48%
Loosely correlated
-2.28%
SYRE - AGIO
46%
Loosely correlated
-4.51%
IDYA - AGIO
46%
Loosely correlated
-5.16%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-5.16%
IMNM - IDYA
61%
Loosely correlated
-5.64%
CGON - IDYA
60%
Loosely correlated
-3.80%
SYRE - IDYA
60%
Loosely correlated
-4.51%
NRIX - IDYA
59%
Loosely correlated
-3.63%
XENE - IDYA
58%
Loosely correlated
-1.84%
More